Halozyme Therapeutics' stock soared 7.71% during intraday trading on Tuesday, extending gains from pre-market activity.
The surge follows the biotechnology company's better-than-expected first-quarter results, where it reported adjusted earnings per share of $1.6, surpassing the IBES estimate of $1.53. This positive earnings surprise triggered significant buying interest.
Adding to the momentum, analysts have expressed optimism towards Halozyme. H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on the stock and set a price target of $95.00, highlighting continued positive sentiment from the investment community.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments